Home › Funds › MAVERICK CAPITAL LTD › NAMS
MAVERICK CAPITAL LTD position in NAMS
NEWAMSTERDAM PHARMA COMPANY · Health Care
MAVERICK CAPITAL LTD reported holding 1,855,630 shares of NAMS (NEWAMSTERDAM PHARMA COMPANY) in its Q3 2026 13F filing — a position valued at US$45.1M, representing 0.37% of its reported portfolio and ranking #41 among its reported holdings. MAVERICK CAPITAL LTD has disclosed NAMS holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How MAVERICK CAPITAL LTD's NAMS position evolved
MAVERICK CAPITAL LTD first disclosed a stake in NAMS in Q4 2024 at 350,005 shares (US$9.0M). The position peaked in Q2 2026 at 3,267,802 shares, worth US$110.7M. Across 8 filings, MAVERICK CAPITAL LTD increased the stake 5 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,855,630 shares valued at US$45.1M — a reduction of -1,412,172 shares quarter over quarter.. Notable position changes include a 57% increase in Q1 2025 (shares fell 8% over the following quarter), a 179% increase in Q2 2025 (shares rose 50% over the following quarter), a 49% increase in Q2 2026 (shares fell 32% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 350.00K | $9.00M | New |
| Q1 2025 | 549.47K | $11.25M | Add |
| Q2 2025 | 1.53M | $27.74M | Add |
| Q3 2025 | 1.50M | $42.80M | Reduce |
| Q4 2025 | 1.89M | $66.45M | Add |
| Q1 2026 | 2.19M | $69.99M | Add |
| Q2 2026 | 3.27M | $110.75M | Add |
| Q3 2026 | 1.86M | $45.13M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NAMS and 13F data
NAMS (NEWAMSTERDAM PHARMA COMPANY) is a Health Care company. 34 other funds we track also report a position in NAMS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$461.8M), RA CAPITAL MANAGEMENT, L.P. (US$232.3M), FCPM III SERVICES B.V. (US$206.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NAMS
- Frazier Life Sciences Management, L.P. 18.99M sh · $461.81M · Q3 2026
- RA CAPITAL MANAGEMENT, L.P. 9.55M sh · $232.26M · Q3 2026
- FCPM III SERVICES B.V. 8.49M sh · $206.49M · Q3 2026
- Maverick Capital 3.27M sh · $110.75M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 4.25M sh · $103.46M · Q3 2026
- Bain Capital Life Sciences Investors, LLC 3.81M sh · $92.58M · Q3 2026
- Duquesne Family Office LLC 3.36M sh · $81.65M · Q3 2026
- Medicxi Ventures Management (Jersey) Ltd 2.18M sh · $53.07M · Q3 2026
More on MAVERICK CAPITAL LTD
FAQ
How long has MAVERICK CAPITAL LTD held NAMS?
MAVERICK CAPITAL LTD has disclosed NAMS holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is MAVERICK CAPITAL LTD's current position in NAMS?
As of Q3 2026, MAVERICK CAPITAL LTD holds 1.86M shares of NAMS (NEWAMSTERDAM PHARMA COMPANY), valued at $45.13M, representing 0.37% of its reported portfolio and ranking #41.
Has MAVERICK CAPITAL LTD been buying or selling NAMS?
In the latest 13F filing (Q3 2026), MAVERICK CAPITAL LTD reduced its position in NAMS. The position peaked in Q2 2026 at 3.27M shares.
Which other funds hold NAMS?
Other major institutional holders of NAMS include Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., FCPM III SERVICES B.V., among 34 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.